Inmaculada Concepción Villar
University of Granada
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Inmaculada Concepción Villar.
Journal of Hypertension | 2006
Manuel Castro Sánchez; Milagros Galisteo; Rocio Vera; Inmaculada Concepción Villar; Antonio Zarzuelo; Juan Tamargo; Francisco Perez-Vizcaino; Juan Duarte
Background and objective Several studies have found that chronic treatment with the dietary flavonoid quercetin lowers blood pressure and restores endothelial dysfunction in hypertensive animal models. We hypothesized that increased endothelial nitric oxide synthase (eNOS) and/or decreased nicotinamide adenine dinucleotide phosphate (NADPH) oxidase protein expression and activity, and reduced reactive oxygen species might be involved in the improvement of endothelial function induced by quercetin in sponataneously hypertensive rats (SHR). Design and methods Male SHR and Wistar–Kyoto (WKY) rats (5 weeks old) were treated with quercetin (10 mg/kg) or vehicle for 13 weeks. Changes in vascular expression of eNOS, caveolin-1 and p47phox were analysed by Western blot, eNOS activity by conversion of [3H]arginine to L-[3H]citrulline, and NADPH oxidase activity by NADPH-enhanced chemoluminescence of lucigenin. Results In SHR, quercetin reduced the increase in blood pressure and heart rate and enhanced the endothelium-dependent aortic vasodilation induced by acetylcholine, but had no effect on the endothelium-independent response induced by nitroprusside. However, quercetin had no effect on endothelium-dependent vasoconstriction and aortic thromboxane B2 production. Compared to WKY, SHR showed upregulated eNOS and p47phox protein expression, downregulated caveolin-1 expression, increased NADPH-induced superoxide production but, paradoxically, eNOS activity was reduced. Chronic quercetin treatment prevented all these changes in SHR. In WKY, quercetin had no effect on blood pressure, endothelial function or the expression or activity of the proteins analysed. Conclusions Enhanced eNOS activity and decreased NADPH oxidase-mediated superoxide anion (O2−) generation associated with reduced p47phox expression appear to be essential mechanisms for the improvement of endothelial function and the antihypertensive effects of chronic quercetin.
Molecular and Cellular Biochemistry | 2005
María Francisca García-Saura; Milagros Galisteo; Inmaculada Concepción Villar; Almudena Bermejo; Antonio Zarzuelo; Félix Vargas; Juan Duarte
The aims of the present study were to analyse the effects of an oral daily dose (10 mg/kg) of the dietary flavonoid quercetin for five weeks in two-kidney, one-clip (2K1C) Goldblatt (GB) hypertensive rats. The evolution of systolic blood pressure was followed by weekly measurements, and morphological variables, proteinuria, plasma nitrates plus nitrites (NOx) and thiobarbituric acid reactive substances (TBARS), liver oxidative stress markers and endothelial function were determined at the end of the experimental period. Quercetin treatment reduced systolic blood pressure of GB rats, producing no effect in control animals. It also reduced cardiac hypertrophy and proteinuria developed in GB hypertensive rats. Decreased endothelium-dependent relaxation to acetylcholine of aortic rings from GB rats was improved by chronic quercetin treatment, as well as increased endothelium-dependent vasoconstrictor response to acetylcholine and overproduction of TXB2 by aortic vessels of GB rats, being without effect in normotensive animals. Increased plasma NOx and TBARS, and decreased liver total glutathione (GSH) levels and glutathione peroxidase (GPX) activity were observed in GB hypertensive rats compared to the control animals. Normalisation of plasma NOx and TBARS concentrations and improvement of the antioxidant defences system in liver accompanied the antihypertensive effect of quercetin. We conclude that chronic oral treatment with quercetin shows both antihypertensive and antioxidant effects in this model of renovascular hypertension. (Mol Cell Biochem 270: 147–155, 2005)
Clinical Science | 2007
Rocio Vera; Manuel Castro Sánchez; Milagros Galisteo; Inmaculada Concepción Villar; Rosario Jiménez; Antonio Zarzuelo; Francisco Perez-Vizcaino; Juan Duarte
The soya-derived phytoestrogen genistein has been suggested to be protective in cardiovascular diseases. In the present study, we have analysed whether chronic oral genistein might influence endothelial function in male SHRs (spontaneously hypertensive rats) via ERs (oestrogen receptors), changes in eNOS (endothelial NO synthase) activity and vascular O(2)(-) (superoxide) production. Rats (23-weeks old) were divided into the following groups: WKY (Wistar-Kyoto)-vehicle, SHR-vehicle, WKY-genistein (10 mg.kg(-1) of body weight.day(-1)); SHR-genistein; SHR-genistein-faslodex (ICI 182780; 2.5 mg.kg(-1) of body weight.day(-1)). Vascular expression of eNOS, caveolin-1 and calmodulin-1 were analysed by Western blotting, eNOS activity by conversion of [(3)H]arginine into L-[(3)H]citrulline and O(2)(-) production by chemoluminescence of lucigenin. In SHRs, after 5 weeks of treatment, genistein reduced systolic blood pressure and enhanced endothelium-dependent aortic relaxation to acetylcholine, but had no effect on the vasodilator responses to sodium nitroprusside. Compared with WKY rats, SHRs had up-regulated eNOS and down-regulated caveolin-1 and calmodulin-1 expression, increased NADPH-induced O(2)(-) production, but reduced eNOS activity. Genistein increased aortic calmodulin-1 protein abundance and eNOS activity, and reduced NADPH-induced O(2)(-) production in SHRs. The pure ERalpha and ERbeta antagonist faslodex did not modify any of the changes induced by genistein in SHRs, suggesting that these effects are unrelated to ER stimulation. In conclusion, genistein reduced the elevated blood pressure and endothelial dysfunction in SHRs. This latter effect appears to be related to increased eNOS activity associated with increased calmodulin-1 expression and decreased O(2)(-) generation.
Molecular and Cellular Biochemistry | 2004
Milagros Galisteo; María Francisca García-Saura; Rosario Jiménez; Inmaculada Concepción Villar; Antonio Zarzuelo; Félix Vargas; Juan Duarte
We investigated the potential of chronic administration of an oral daily dose (10 mg/kg) of the dietary flavonoid quercetin to prevent hypertension and oxidative stress induced by deoxycorticosterone acetate (DOCA)-salt in rats. We have compared its effects to those produced by the well-known anti-hypertensive drug verapamil, administered orally (20 mg/kg/day). Quercetin and verapamil treatments reduced systolic blood pressure of DOCA-salt rats in approximately 67.6 and 63.3% respectively, producing no effect in control animals. Both drugs reduced significantly hepatic and renal hypertrophy induced by DOCA-salt administration, while only quercetin prevented cardiac hypertrophy. Decreased endothelium-dependent relaxation to acetylcholine of aortic rings from DOCA-salt-treated rats was improved by quercetin, but verapamil only enhanced it in the presence of superoxide dismutase (SOD) plus catalase. Increased plasma and heart thiobarbituric acid reactive substances (TBARS) and total glutathione (GSH) levels in liver and heart, decreased liver glutathione peroxidase (GPX) and liver and kidney glutathione transferase (GST) activities were observed in DOCA-salt-treated rats compared to the control animals. The antihypertensive effect of quercetin was accompanied by normalisation of plasma TBARS values, improvement of the antioxidant defences system in heart and liver, restoring total GSH levels in both organs and altered liver GST and GPX activities, and improving kidney GST activity. Verapamil treatment only restored GSH levels in heart, having no effect on other alterations induced by DOCA-salt chronic administration in the antioxidant defences analysed. In conclusion, quercetin shows both antihypertensive and antioxidant properties in this model of mineralocorticoid hypertension, while verapamil exhibits only antihypertensive effects.
Journal of Vascular Research | 2004
Inmaculada Concepción Villar; Milagros Galisteo; Rocio Vera; Francisco O'Valle; María Francisca García-Saura; Antonio Zarzuelo; Juan Duarte
In the present study, the effects of the bioflavonoid chrysin (5,7-dihydroxyflavone) were analyzed on the perfusion pressure of isolated mesenteric vascular bed. The vasorelaxant effects of chrysin were more potent on intact endothelium than on denuded vessels. This endothelium-dependent response induced by chrysin was inhibited in the presence of NG-nitro-L-arginine methyl ester (L-NAME), KCl, tetraethylammonium (TEA), BaCl2, TEA plus L-NAME, and ouabain plus BaCl2, while incubations with indomethacin and glibenclamide did not modify the response induced by this bioflavonoid. Neither gap junction inhibition with carbenoxolone nor epoxyeicosatrieconic acid synthesis inhibition with sulfaphenazole (selective CYP 2C/3A inhibitor) or 7-ethoxyresorufin (selective CYP 1A inhibitor) inhibited the chrysin-induced relaxation. Moreover, chrysin increased L-NAME-sensitive cGMP accumulation in intact vascular mesenteric preparation. In conclusion, chrysin shows vasodilator effects on resistance vessels, which depend partially on the functional endothelium and appear to be related to the NO/cGMP pathway and, possibly to the release of endothelium-derived hyperpolarizing factor.
Journal of Nutrition | 2007
Manuel Castro Sánchez; Federica Lodi; Rocio Vera; Inmaculada Concepción Villar; Angel Cogolludo; Rosario Jiménez; Laura Moreno; Miguel Romero; Juan Tamargo; Francisco Perez-Vizcaino; Juan Duarte
Planta Medica | 2002
Inmaculada Concepción Villar; Rosario Jiménez; Milagros Galisteo; María Francisca García-Saura; Antonio Zarzuelo; Juan Duarte
Journal of Pharmacology and Experimental Therapeutics | 2005
Rocio Vera; Milagros Galisteo; Inmaculada Concepción Villar; Manuel Castro Sánchez; Antonio Zarzuelo; Francisco Perez-Vizcaino; Juan Duarte
Planta Medica | 2001
Juan Duarte; Rosario Jiménez; Inmaculada Concepción Villar; Francisco Perez-Vizcaino; Jose Beltran Jimenez; Juan Tamargo
Planta Medica | 2004
Milagros Galisteo; María Francisca García-Saura; Rosario Jiménez; Inmaculada Concepción Villar; Rosemary Wangensteen; Antonio Zarzuelo; Félix Vargas; Juan Duarte